Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. decreased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 50.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 174,200 shares of the company's stock after selling 177,900 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.59% of Dianthus Therapeutics worth $4,508,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after acquiring an additional 384,182 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock valued at $2,095,000 after purchasing an additional 72,509 shares during the period. Octagon Capital Advisors LP lifted its stake in shares of Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company's stock valued at $5,762,000 after purchasing an additional 74,000 shares during the period. Vestal Point Capital LP purchased a new stake in Dianthus Therapeutics during the fourth quarter worth $1,404,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its position in Dianthus Therapeutics by 281.9% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company's stock valued at $1,022,000 after buying an additional 29,159 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

NASDAQ DNTH traded down $0.52 during mid-day trading on Thursday, hitting $27.46. The stock had a trading volume of 261,675 shares, compared to its average volume of 191,965. The firm's 50 day moving average is $27.90 and its 200 day moving average is $26.21. The stock has a market capitalization of $805.92 million, a price-to-earnings ratio of -4.80 and a beta of 1.85. Dianthus Therapeutics, Inc. has a twelve month low of $6.58 and a twelve month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on DNTH. Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an "overweight" rating for the company. Wedbush reduced their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, August 9th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 price objective for the company. Finally, Baird R W upgraded Dianthus Therapeutics to a "strong-buy" rating in a research report on Friday, July 26th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $45.13.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.